公开(公告)号：US11825819B2

公开(公告)日：2023-11-28

申请号：US17061978

申请日：2020-10-02

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： Claudia Gonzaga-Jauregui ,  Sokol Haxhinasto ,  Zaruhi Hovhannisyan ,  Kavita Praveen

IPC分类号： A01K67/027 ,  A61K49/00

CPC分类号： A01K67/0276 ,  A61K49/0008 ,  A01K2217/054 ,  A01K2217/056 ,  A01K2227/105 ,  A01K2267/0368

摘要： This disclosure relates to a genetically modified rodent and use thereof as a rodent model. More specifically, this disclosure relates to rodent (e.g., mouse or rat) comprising a loss of function mutation in an endogenous Crnn (cornulin) gene, and to use of such a rodent animal as a rodent model of skin inflammation disorders (e.g., psoriasis).

公开(公告)号：US20240327489A1

公开(公告)日：2024-10-03

申请号：US18580770

申请日：2022-07-20

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Casandra M. Panea ,  Sokol Haxhinasto ,  Zaruhi Hovhannisyan ,  Julie Horowitz

IPC分类号： C07K14/705 ,  A61K38/00 ,  A61K39/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/28 ,  G01N33/50

CPC分类号： C07K14/70503 ,  A61P29/00 ,  A61P37/06 ,  C07K16/2803 ,  G01N33/505 ,  A61K38/00 ,  A61K2039/505 ,  C07K2319/33

摘要： This disclosure provides methods for treating T cell-driven inflammatory disorders. The methods include administering to a subject a therapeutically effective amount of a butyrophilin-like 2 (Btnl2) agent capable of increasing a level or activity of Btnl2, thereby altering the frequencies or function of lymphocytes in the subject.

公开(公告)号：US20230172172A1

公开(公告)日：2023-06-08

申请号：US18159414

申请日：2023-01-25

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Andrew J. Murphy ,  Alexander O. Mujica ,  Ka-Man Venus Lai ,  Sokol Haxhinasto ,  Zaruhi Hovhannisyan

IPC分类号： A01K67/027 ,  C07K16/24 ,  C07K16/28 ,  C12N15/85

CPC分类号： A01K67/0278 ,  C07K16/244 ,  C07K16/2866 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2227/105 ,  C07K2317/24 ,  C07K2317/76 ,  C12N2015/8527 ,  A01K2267/0368 ,  A01K2217/15

摘要： This disclosure relates to genetically modified rodent animals and rodent models of human diseases. More specifically, this disclosure relates to genetically modified rodents whose genome comprises a humanized Il1rl2 gene (coding for the IL1rl2 subunit of the IL-36R protein) and human IL-36α, β and γ ligand genes. The genetically modified rodents disclosed herein display enhanced skin and intestinal inflammation as a preclinical model of psoriasis and IBD, respectively, and serve as a rodent model of human DITRA disease.

公开(公告)号：US20200015462A1

公开(公告)日：2020-01-16

申请号：US16512949

申请日：2019-07-16

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Andrew J. Murphy ,  Alexander O. Mujica ,  Ka-Man Venus Lai ,  Sokol Haxhinasto ,  Zaruhi Hovhannisyan

IPC分类号： A01K67/027 ,  C07K16/24 ,  C07K16/28 ,  C12N15/85

摘要： This disclosure relates to genetically modified rodent animals and rodent models of human diseases. More specifically, this disclosure relates to genetically modified rodents whose genome comprises a humanized Il1rl2 gene (coding for the IL1rl2 subunit of the IL-36R protein) and human IL-36α, β and γ ligand genes. The genetically modified rodents disclosed herein display enhanced skin and intestinal inflammation as a preclinical model of psoriasis and IBD, respectively, and serve as a rodent model of human DITRA disease.